Private equity firm snaps up JHP for $195M

Contract manufacturer JHP Pharmaceuticals is now the property of private equity giant Warburg Pincus, as the company is spending $195 million to buy the CMO. JHP specializes in sterile injectables, and, with Warburg Pincus' backing, the company will be able to expand its generics manufacturing in the coming years, JHP CEO Stuart Hinchen said. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.